JBH492
Phase 1Terminated 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Non-Hodgkins Lymphoma
Conditions
Non-Hodgkins Lymphoma, Chronic Lymphocytic Leukemia
Trial Timeline
Sep 7, 2020 → Sep 5, 2024
NCT ID
NCT04240704About JBH492
JBH492 is a phase 1 stage product being developed by Novartis for Non-Hodgkins Lymphoma. The current trial status is terminated. This product is registered under clinical trial identifier NCT04240704. Target conditions include Non-Hodgkins Lymphoma, Chronic Lymphocytic Leukemia.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04240704 | Phase 1 | Terminated |
Competing Products
15 competing products in Non-Hodgkins Lymphoma
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Acalabrutinib + ACP-319 | AstraZeneca | Phase 1/2 | 41 |
| Glofitamab + Atezolizumab + Obinutuzumab + Tocilizumab + Polatuzumab Vedotin + 89Zr-Df-IAB22M2C | Roche | Phase 1/2 | 41 |
| Obinutuzumab + Glofitamab + Gemcitabine + Oxaliplatin | Roche | Phase 2 | 52 |
| Cyclophosphamide + Mitoxantrone + Vincristine + Prednisone + Rituximab | Amgen | Phase 2 | 51 |
| hLL2 (epratuzumab) | Gilead Sciences | Phase 1 | 32 |
| Velcade + Temsirolimus | Pfizer | Phase 2 | 51 |
| alemtuzumab | Sanofi | Phase 1/2 | 40 |
| Odronextamab + REGN5837 | Regeneron Pharmaceuticals | Phase 1 | 32 |
| Rituximab + 90Y ibritumomab tiuxetan (Zevalin) + Cyclophosphamide + Fludarabine | Bayer | Phase 1/2 | 38 |
| Rituximab + Fludarabine + CAMPTH-1H | Bayer | Phase 2 | 49 |
| Rituximab + CHOP + CVP + Ibritumomab Tiuxetan | Biogen | Phase 2 | 49 |
| Ifosfamide + Carboplatin + Etoposide + Rituximab + 90Y Zevalin | Biogen | Phase 2 | 49 |
| Ublituximab | TG Therapeutics | Phase 1/2 | 38 |
| Ublituximab + Lenalidomide | TG Therapeutics | Phase 1 | 30 |
| XmAb13676 | Xencor | Phase 1 | 28 |